Unbiased and Practical Psychopharmacology Updates For Prescribers
Recent articles and videos
In this episode, we discuss part of Dr. David Osser’s (Harvard Medical School) PTSD algorithm about treating sleep symptoms of PTSD. We cover the evidence on prazosin’s efficacy and trazodone use. The rationale behind certain drugs to avoid is also covered.
This presentation summarizes the benefits of obtaining antipsychotic plasma levels in nonresponding patients.
In this episode, we review principles of prescribing psychotropics in patients with liver, kidney and lung diseases with Dr. James Levenson (Virginia Commonwealth University).
In this episode, we learn to prescribe with the gut in mind. Dr. James Levenson (Virginia Commonwealth University) joins us with to-the-point tips on prescribing psychotropics in patients with GI disease as well as exploring how psychotropics can affect the GIT.
In this episode, we uncover clinical pearls of geriatric psychopharmacology. We are joined by Dr. Sandra Jacobson of the University of Arizona giving practical tips on prescribing for this special group of patients.
In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.
MDMA (3,4-methylenedioxymethamphetamine) is being studied for treatment-resistant PTSD. This presentation discusses results from clinical and neuroimaging studies.
In this episode, we venture into the psychopharmacology of agitation, with a special focus on psychotic agitation. Dr. Michael Jibson (University of Michigan) and Dr. David Osser (Harvard Medical School) shared clinical pearls to treat this challenging situation.
This presentation reviews the effects of serotonin receptors (5-HTR) on domains such as impulsivity/aggression, anxiety/stress, and cognition. It also discusses findings from neuroimaging studies involving 5-HT1A and 5-HT2A receptors.
This presentation discusses how to address partial response to pharmacotherapy in the treatment of GAD. When to switch and when to augment. Dr. Osser gives three options for augmentation.